新型皮肤分期系统与毛囊性蕈样肉芽肿预后变量的关联:美国队列研究
多变量Cox回归显示,仅年龄与总生存显著相关(每增加10岁HR 3.1),仅皮肤分期与疾病特异性生存显著相关(HR 11.4)。早期与晚期皮肤分期的生存曲线有效区分,支持FMF异质性及新分期系统的预后效用。
要点
- 新皮肤分期系统可有效区分FMF早期与晚期患者的生存。
- 多变量分析中仅皮肤分期与疾病特异性生存显著相关。
- 年龄是总生存的唯一显著预测变量。
核心结论
- Cox回归模型显示皮肤分期是唯一与疾病特异性生存显著相关的预测变量。
- 将FMF分为早期和晚期皮肤分期可有效估计该队列的生存。
- FMF是异质性疾病,初期认为的不良预后仅适用于晚期皮肤分期。
研究设计与样本
- 数据分析时间为2018年1月1日至2020年8月31日。
- 采用Kaplan-Meier曲线估计总生存和疾病特异性生存,Cox比例风险回归评估预测变量。
主要发现
- 整个队列5年总生存率89%(95%CI 79%-99%),10年78%(95%CI 63%-92%),15年58%(95%CI 31%-85%)。
- 5年和10年疾病特异性生存率均为89%(95%CI 79%-99%),15年80%(95%CI 61%-99%)。
- 早期皮肤分期5年总生存率96%(95%CI 89%-103%),10年82%(95%CI 65%-98%),15年65%(95%CI 33%-97%);晚期皮肤分期5年和10年总生存率均为70%(95%CI 41%-98%),15年53%(95%CI 16%-89%)。
临床怎么用
- 临床可采用新皮肤分期系统对FMF患者进行早期与晚期分层,以辅助预后评估。
- 对晚期皮肤分期患者应加强监测与干预,因其预后较差。
局限性
- 为单中心回顾性队列,存在选择偏倚与随访信息缺失可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A new cutaneous staging system for folliculotropic mycosis fungoides (FMF) has been purported to better estimate survival compared with the staging system for conventional mycosis fungoides. OBJECTIVE: To analyze predictive variables associated with survival and evaluate the effectiveness of the newly proposed staging system for estimating overall survival and disease-specific survival (DSS) in a US cohort. DESIGN, SETTING, AND PARTICIPANTS: This cohort study assessed 195 patients with FMF in the dermatopathology database of the University of California, San Francisco from January 1, 1990, to April 31, 2012, for eligibility. A total of 153 patients were excluded for the following reasons: (1) alternative diagnoses were favored ranging from benign dermatitides to other forms of cutaneous lymphoma; (2) technical problems with slides; and (3) lack of follow-up information. Data were analyzed from January 1, 2018, to August 31, 2020. MAIN OUTCOMES AND MEASURES: Kaplan-Meier curves were used to estimate overall survival and DSS for the entire cohort. Possible predictive variables associated with survival were evaluated using Cox proportional hazards regression modeling. Each variable was examined separately, followed by a multiple-variable model. Kaplan-Meier curves were used to estimate overall survival and DSS by subdividing the cohort into early- and advanced-stage cutaneous disease. RESULTS: Forty-two patients were included in the analysis (mean age at diagnosis, 55 [range, 8-89] years; 31 men [74%]). For the entire cohort, the estimated 5-year overall survival rate was 89% (95% CI, 79%-99%); 10-year rate, 78% (95% CI, 63%-92%); and 15-year rate, 58% (95% CI, 31%-85%). Estimated 5- and 10-year DSS rates were 89% (95% CI, 79%-99%); 15-year rate, 80% (95% CI, 61%-99%). For overall survival in the multiple-variable Cox proportional hazards regression model, only age was statistically significant (hazard ratio [HR] per 10-year age increase, 3.1; 95% CI, 1.4-7.2; P = .008), whereas for DSS, only cutaneous disease was statistically significant (HR, 11.4; 95% CI, 1.3-103.0; P = .03). When stage stratified, the 5-year estimated overall survival rate for early-stage disease was 96% (95% CI, 89%-103%); 10-year rate, 82% (95% CI, 65%-98%); and 15-year rate, 65% (95% CI, 33%-97%). For advanced-stage disease, the estimated 5- and 10-year overall survival rates were 70% (95% CI, 41%-98%); the 15-year rate, 53% (95% CI, 16%-89%). For early-stage cutaneous disease, the estimated 5-, 10- and 15-year DSS rates were all 96% (95% CI, 89%-103%). For advanced-stage cutaneous disease, the estimated 5- and 10-year DSS rates were 70% (95% CI, 41%-98%); the 15-year rate, 53% (95% CI, 16%-89%). CONCLUSIONS AND RELEVANCE: Cox proportional hazards regression modeling demonstrated cutaneous stage to be the only statistically significant predictive variable associated with DSS. Subdividing FMF into early and advanced cutaneous stages was associated with effective estimation of survival in this cohort. Thus, findings suggest that FMF is a heterogeneous disease with early and advanced cutaneous stages; that the new staging system is effective in estimating survival in a US cohort; and that the poor prognosis initially associated with FMF only applies to the advanced cutaneous stage.
引用
- Charli-Joseph Y, Kashani-Sabet M, McCalmont TH, et al. Association of a Proposed New Staging System for Folliculotropic Mycosis Fungoides With Prognostic Variables in a US Cohort. JAMA Dermatol. 2021. PMID: 33295938. doi:10.1001/jamadermatol.2020.4372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。